Current oncology (Toronto), 2024-04, Vol.31 (4), p.2274-2277
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients
- Ist Teil von
- Current oncology (Toronto), 2024-04, Vol.31 (4), p.2274-2277
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2024
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Maintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphotericin B was started. Oncologists should bear in mind that visceral leishmaniasis in endemic areas can potentially induce severe and prolonged pancytopenia in immunosuppressed patients, during chemotherapy in particular.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1718-7729, 1198-0052eISSN: 1718-7729DOI: 10.3390/curroncol31040168Titel-ID: cdi_doaj_primary_oai_doaj_org_article_5b1f4f27b26d4a12bf97b7ca459f8527
- Format
- –
- Schlagworte
- Amphotericin B - therapeutic use, Anemia, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Antiprotozoal Agents - therapeutic use, Cancer, Cancer patients, Carcinoma, Non-Small-Cell Lung - drug therapy, Chemotherapy, Diagnosis, Differential, Drug therapy, Health aspects, Humans, Immunotherapy, Kala-azar, Leishmaniasis, Visceral - complications, Leishmaniasis, Visceral - diagnosis, Leishmaniasis, Visceral - drug therapy, lung cancer, Lung cancer, Non-small cell, Lung Neoplasms - drug therapy, Male, Middle Aged, pancytopenia, Pancytopenia - chemically induced, Pemetrexed, Pemetrexed - adverse effects, Pemetrexed - therapeutic use, visceral leishmaniasis